Celldex Therapeutics (NASDAQ:CLDX) takes a hit in the post session after releasing mixed preliminary results from randomized Phase 2b tests of CDX-011 antibody drug conjugate in patients with advanced, heavily pretreated breast cancer. Shares -8.5% AH.
Celldex Therapeutics (NASDAQ:CLDX) takes a hit in the post session after releasing mixed...
Recommended For You
About CLDX Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| CLDX | - | - |
| Celldex Therapeutics, Inc. | ||